Effectiveness Of Pegcetacoplan In Preserving Visual Function In Geographic Atrophy
Dr Charles Wykoff presents the results of a post hoc microperimetry analysis from the OAKS study demonstrating the effectiveness of pegcetacoplan in preserving visual function.
This is a video synopsis of a discussion involving Charles C. Wykoff, MD, PhD, where he presents key findings from a study on the long-term utilization of pegcetacoplan (complement C3 inhibitor) in patients with geographic atrophy (GA). The study, named GALE, extends beyond the preceding DERBY and OAKS trials, focusing on the microperimetry data.
Dr. Wykoff emphasizes the significance of microperimetry in understanding visual function from a patient's perspective, particularly in relation to challenges with best-corrected visual acuity and other functional markers. The analysis of microperimetry data reveals a correlation between the preservation of at least one of the four central loci and less vision loss. Patients who lost all four loci during the trial experienced an average loss of 11.7 letters, while those preserving at least one lost only 4.9 letters.
Moreover, a post hoc analysis indicates a 34-36% risk reduction over two years for patients using pegcetacoplan in losing all four central loci. A similar correlation is observed when examining all 16 central macular loci, showing a 43-48% risk reduction in losing these spots over two years with pegcetacoplan.
Dr. Wykoff concludes by highlighting the continued reduction in lesion expansion observed in the GALE study, aligning with the outcomes of DERBY and OAKS trials. Safety signals remain consistent with preceding trials. The GALE study is ongoing, with plans to accumulate three years of data, bringing the total to five years, including continuous pegcetacoplan dosing.
In anticipation of forthcoming data, Dr. Wykoff mentions the phase four trial, GARLAND, an observational study on geographic atrophy involving approximately 300 patients across 30 sites in the United States. This three-year open-label observational study aims to assess real-world safety and efficacy of Pegcetacoplan in GA treatment. The presentation concludes with Dr. Wykoff expressing enthusiasm for sharing more GA treatment data in the months and years to come.
Video synopsis is AI-generated and reviewed by Modern Retina® editorial staff.
